共 155 条
[21]
Capdevila J(2019)Symptomatic and radiological response to 177Lu-DOTATATE for the treatment of functioning pancreatic neuroendocrine tumors J Clin Endocrinol Metab 104 1336-2259
[22]
Gross D(2019)Quality of life in patients with midgut NET following peptide receptor radionuclide therapy Eur J Nucl Med Mol Imaging 46 2252-1422
[23]
Kianmanesh R(2017)Health-related quality of life for everolimus versus placebo in patients with advanced, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (RADIANT-4): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial Lancet Oncol 18 1411-327
[24]
Caplin ME(2019)Observational study to assess quality of life in patients with pancreatic neuroendocrine tumors receiving treatment with everolimus: the OBLIQUE study (UK phase IV trial) Neuroendocrinology 108 317-824
[25]
Pavel M(2016)Patient-reported outcomes and quality of life with sunitinib versus placebo for pancreatic neuroendocrine tumors: results from an international phase III trial Target Oncol 11 815-19
[26]
Cwikla JB(2021)Final overall survival in the phase 3 NETTER-1 study of lutetium-177-DOTATATE in patients with midgut neuroendocrine tumors J Clin Oncol 39 4112-undefined
[27]
Phan AT(2015)Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors Eur J Nucl Med Mol Imaging 42 5-undefined
[28]
Raderer M(undefined)undefined undefined undefined undefined-undefined
[29]
Sedlackova E(undefined)undefined undefined undefined undefined-undefined
[30]
Rinke A(undefined)undefined undefined undefined undefined-undefined